Newborn

Register      Login

SEARCH WITHIN CONTENT

FIND ARTICLE

Volume / Issue

Online First

Archive
Volume  3 (2024)
Volume  2 (2023)
Volume  1 (2022)
Related articles

VOLUME 1 , ISSUE 3 ( July-September, 2022 ) > List of Articles

REVIEW ARTICLE

Use of Fresh-frozen Plasma in Newborn Infants

Keywords : Coagulation tests, Disseminated intravascular coagulation, Fresh-frozen plasma, Hemorrhages, Plasmapheresis, Relative risk, Whole-blood donor units

Citation Information : Use of Fresh-frozen Plasma in Newborn Infants. 2022; 1 (3):271-277.

DOI: 10.5005/jp-journals-11002-0039

License: CC BY-NC 4.0

Published Online: 07-10-2022

Copyright Statement:  Copyright © 2022; The Author(s).


Abstract

Nearly 10% of premature and critically ill infants receive fresh-frozen plasma (FFP) transfusions to reduce their high risk of bleeding. The authors have only limited data to identify relevant clinical predictors of bleeding and to evaluate the efficacy of FFP administration. There is still no consensus on the optimal use of FFP in infants who have abnormal coagulation parameters but are not having active bleeding. The aims of this review are to present current evidence derived from clinical studies focused on the use of FFP in neonatology and then use these data to propose best practice recommendations for the safety of neonates receiving FFP.

Supplementary File

PDF Share
  1. Dzik W, Rao A. Why do physicians request fresh frozen plasma? Transfusion 2004;44(9):1393–1394. DOI: 10.1111/j.0041-1132.2004.00422.x.
  2. Neary E, McCallion N, Kevane B, et al. Coagulation indices in very preterm infants from cord blood and postnatal samples. J Thromb Haemost 2015;13(11):2021–2030. DOI: 10.1111/jth.13130.
  3. Howick J, Chalmers I, Glasziou P, et al. The 2011 Oxford CEBM Evidence Levels of Evidence (Introductory Document). Oxford Centre for Evidence-Based Medicine. 2022. https://www.cebm.ox.ac.uk/resources/levels-of-evidence/levels-of-evidence-introductory-document.
  4. Girelli G, Antoncecchi S, Casadei AM, et al. Recommendations for transfusion therapy in neonatology. Blood Transfus 2015;13(3): 484–497. DOI: 10.2450/2015.0113-15.
  5. Gross SJ, Filston HC, Anderson JC. Controlled study of treatment for disseminated intravascular coagulation in the neonate. J Pediatr 1982;100(3):445–448. DOI: 10.1016/s0022-3476(82)80457-5.
  6. Neary E, Ni Ainle F, El-Khuffash A, et al. Plasma transfusion to prevent intraventricular haemorrhage in very preterm infants. Cochrane Database Syst Rev 2016;9:CD012341. DOI: 10.1002/14651858.CD012341.
  7. Pal S, Curley A, Stanworth SJ. Interpretation of clotting tests in the neonate. Arch Dis Child Fetal Neonatal Ed 2015;100(3):F270–274. DOI: 10.1136/archdischild-2014-306196.
  8. Wallis JP, Dzik S. Is fresh frozen plasma overtransfused in the United States? Transfusion 2004;44(11):1674–165. DOI: 10.1111/j.0041-1132.2004.00427.x.
  9. Andrew M, Paes B, Milner R, et al. Development of the human coagulation system in the full-term infant. Blood 1987;70(1):165–172. PMID: 3593964.
  10. Andrew M, Paes B, Milner R, et al. Development of the human coagulation system in the healthy premature infant. Blood 1988; 72(5):1651–1657. PMID: 3179444.
  11. Christensen RD, Baer VL, Lambert DK, Henry E, Ilstrup SJ, Bennett ST. Reference intervals for common coagulation tests of preterm infants (CME). Transfusion 2014;54(3):627–632: quiz 626. DOI: 10.1111/trf.12322.
  12. Atkins D, Best D, Briss PA, et al. Grading quality of evidence and strength of recommendations. BMJ 2004;328(7454):1490. DOI: 10.1136/bmj.328.7454.1490.
  13. A randomized trial comparing the effect of prophylactic intravenous fresh frozen plasma, gelatin or glucose on early mortality and morbidity in preterm babies. The Northern Neonatal Nursing Initiative [NNNI] Trial Group. Eur J Pediatr 1996;155(7):580–588. DOI: 10.1007/BF01957909.
  14. O'Shaughnessy DF, Atterbury C, Bolton Maggs P, et al. Guidelines for the use of fresh-frozen plasma, cryoprecipitate and cryoupernatant. Br J Haematol 2004;126(1):11–28. DOI: 10.1111/j.1365-2141.2004.04972.x.
  15. Westphal RG, Tindle B, Howard PL, Golden EA, Page GA. Rapid thawing of fresh frozen plasma. Am J Clin Pathol 1982;78(2):220–222. DOI: 10.1093/ajcp/78.2.220.
  16. Gibson BE, Todd A, Roberts I, et al. Transfusion guidelines for neonates and older children. Br J Haematol 2004;124(4):433–453. DOI: 10.1111/j.1365-2141.2004.04815.x.
  17. Liumbruno G, Bennardello F, Lattanzio A, et al. Recommendations for the transfusion of plasma and platelets. Blood Transfus 2009;7(2): 132–150. DOI: 10.2450/2009.0005-09.
  18. Nair PM, Rendo MJ, Reddoch-Cardenas KM, Burris JK, Meledeo MA, Cap AP. Recent advances in use of fresh frozen plasma, cryoprecipitate, immunoglobulins, and clotting factors for transfusion support in patients with hematologic disease. Semin Hematol 2020;57(2):73–82. DOI: 10.1053/j.seminhematol.2020.07.006.
  19. Neary E, Okafor I, Al-Awaysheh F, et al. Laboratory coagulation parameters in extremely premature infants born earlier than 27 gestational weeks upon admission to a neonatal intensive care unit. Neonatology 2013;104(3):222–227. DOI: 10.1159/000353366.
  20. Matsunaga S, Takai Y, Nakamura E, et al. The clinical efficacy of fibrinogen concentrate in massive obstetric haemorrhage with hypofibrinogenaemia. Sci Rep 2017;7:46749. DOI: 10.1038/srep46749.
  21. Pescatore SL. Clinical management of protein C deficiency. Expert Opin Pharmacother 2001;2(3):431–439. DOI: 10.1517/14656566.2.3.431.
  22. Nascimento B, Callum J, Rubenfeld G, et al. Clinical review: fresh frozen plasma in massive bleedings - more questions than answers. Crit Care 2010;14(1):202. DOI: 10.1186/cc8205.
  23. Dogra M, Sidhu M, Vasudev R, Dogra A. Comparative analysis of activity of coagulation factors V and VIII and level of fibrinogen in fresh frozen plasma and frozen plasma. Asian J Transfus Sci 2015; 9(1):6–8. DOI: 10.4103/0973-6247.150936.
  24. Horowitz B, Wiebe ME, Lippin A, et al. Inactivation of viruses in labile blood derivatives. I. Disruption of lipid-enveloped viruses by tri(n-butyl)phosphate detergent combinations. Transfusion 1985;25(6):516–522. DOI: 10.1046/j.1537-2995.1985.25686071422.x.
  25. Liumbruno GM, Franchini M. Solvent/detergent plasma: pharmaceutical characteristics and clinical experience. J Thromb Thrombolysis 2015;39(1):118–128. DOI: 10.1007/s11239-014-1086-1.
  26. Dichtelmuller HO, Biesert L, Fabbrizzi F, et al. Robustness of solvent/detergent treatment of plasma derivatives: A data collection from plasma protein therapeutics association member companies. Transfusion 2009;49(9):1931–1943. DOI: 10.1111/j.1537-2995.2009.02222.x.
  27. de la Rubia J, Arriaga F, Linares D, et al. Role of methylene blue-treated or fresh-frozen plasma in the response to plasma exchange in patients with thrombotic thrombocytopenic purpura. Br J Haematol 2001;114(3):721–723. DOI: 10.1046/j.1365-2141.2001.02991.x.
  28. Shabanian R, Dehestani A, Dadkhah M, et al. Fresh frozen plasma prime and the level of gammaglobulin after pediatric cardiopulmonary bypass. Am J Clin Exp Immunol 2020;9(5):91–100. PMID: 33489477.
  29. Houben NAM, Heeger LE, Stanworth SJ, et al. Changes in the use of fresh-frozen plasma transfusions in preterm neonates: A single center experience. J Clin Med 2020;9(11):3789. DOI: 10.3390/jcm9113789.
  30. Hambleton G, Appleyard WJ. Controlled trial of fresh frozen plasma in asphyxiated low birthweight infants. Arch Dis Child 1973;48(1):31–35. DOI: 10.1136/adc.48.1.31.
  31. Beverley DW, Pitts-Tucker TJ, Congdon PJ, Arthur RJ, Tate G. Prevention of intraventricular haemorrhage by fresh frozen plasma. Arch Dis Child 1985;60(8):710–713. DOI: 10.1136/adc.60.8.710.
  32. Ekblad H, Kero P, Shaffer SG et al. Extracellular volume in preterm infants: influence of gestational age and colloids. Early Hum Dev 1991;27(1–2):1–7. DOI: 10.1016/0378-3782(91)90022-u.
  33. Osborn DA, Evans N. Early volume expansion for prevention of morbidity and mortality in very preterm infants. Cochrane Database Syst Rev 2004;(2):CD002055. DOI: 10.1002/14651858.CD002055.pub2.
  34. Kempny A, Dimopoulos K, Uebing A, et al. Outcome of cardiac surgery in patients with congenital heart disease in England between 1997 and 2015. PLoS One 2017;12(6):e0178963. DOI: 10.1371/journal.pone.0178963.
  35. Mirzaei M, Mirzaei S, Sepahvand E, et al. Evaluation of complications of heart surgery in children with congenital heart disease at Dena Hospital of Shiraz. Glob J Health Sci 2015;8(5):33–38. DOI: 10.5539/gjhs.v8n5p33.
  36. Erdoes G, Gerster G, Colucci G, et al. Prediction of post-weaning fibrinogen status during cardiopulmonary bypass: An observational study in 110 patients. PLoS ONE 2015;10(5):e0126692. DOI: 10.1371/journal.pone.0126692.
  37. Hanson SJ, Karam O, Birch R, et al. Transfusion practices in pediatric cardiac surgery requiring cardiopulmonary bypass: A secondary analysis of a clinical database. Pediatr Crit Care Med 2021;22(11): 978–987. DOI: 10.1097/PCC.0000000000002805.
  38. Ray MJ, Marsh NA, Hawson GA. Relationship of fibrinolysis and platelet function to bleeding after cardiopulmonary bypass. Blood Coagul Fibrinolysis 1994;5(5):679–685. DOI: 10.1097/00001721-199410000-00002.
  39. Hofer J, Fries D, Solomon C, et al. A snapshot of coagulopathy after cardiopulmonary bypass. Clin Appl Thromb Hemost 2016;22(6): 505–511. DOI: 10.1177/1076029616651146.
  40. Desborough M, Sandu R, Brunskill SJ, et al. Fresh frozen plasma for cardiovascular surgery. Cochrane Database Syst Rev 2015;(7):CD007614. DOI: 10.1002/14651858.CD007614.pub2.
  41. Lee JW, Yoo YC, Park HK, et al. Fresh frozen plasma in pump priming for congenital heart surgery: Evaluation of effects on postoperative coagulation profiles using a fibrinogen assay and rotational thromboelastometry. Yonsei Med J 2013;54(3):752–762. DOI: 10.3349/ymj.2013.54.3.752.
  42. Faraoni D, Meier J, New HV, et al. Patient blood management for neonates and children undergoing cardiac surgery: 2019 NATA Guidelines. J Cardiothorac Vasc Anesth 2019;33(12):3249–3263. DOI: 10.1053/j.jvca.2019.03.036.
  43. Holcomb JB, Pati S. Optimal trauma resuscitation with plasma as the primary resuscitative fluid: the surgeon's perspective. Hematol Am Soc Hematol Educ Program 2013;2013:656–659. DOI: 10.1182/asheducation-2013.1.656
  44. Patil V, Shetmahajan M. Massive transfusion and massive transfusion protocol. Indian J Anaesth 2014;58(5):590–595. DOI: 10.4103/0019-5049. 144662.
  45. Levi M, van der Poll T, Buller HR. Bidirectional relation between inflammation and coagulation. Circulation 2004;109(22):2698–2704. DOI: 10.1161/01.CIR.0000131660.51520.9A.
  46. Kaur P, Basu S, Kaur G, et al. Transfusion protocol in trauma. J Emerg Trauma Shock 2011;4(1):103–108. DOI: 10.4103/0974-2700.76844.
  47. Mumford AD, Ackroyd S, Alikhan R, et al. Guideline for the diagnosis and management of the rare coagulation disorders: A United Kingdom Haemophilia Centre Doctors’ Organization guideline on behalf of the British Committee for Standards in Haematology. Br J Haematol 2014;167(3):304–326. DOI: 10.1111/bjh.13058.
  48. Castaman G, Linari S. Diagnosis and treatment of von Willebrand disease and rare bleeding disorders. J Clin Med 2017;6(4): 45. DOI: 10.3390/jcm6040045.
  49. Bray GL, Luban NL. Hemophilia presenting with intracranial hemorrhage. An approach to the infant with intracranial bleeding and coagulopathy. Am J Dis Child 1987;141(11):1215–1217. DOI: 10.1001/archpedi.1987.04460110085030.
  50. Peyvandi F, Menegatti M. Treatment of rare factor deficiencies in 2016. Hematology Am Soc Hematol Educ Program 2016;2016(1):663–669. DOI: 10.1182/asheducation-2016.1.663.
  51. Chalmers E, Williams M, Brennand J, et al. Guideline on the management of haemophilia in the fetus and neonate. Br J Haematol 2011; 154(2):208–215. DOI: 10.1111/j.1365-2141.2010.08545.x.
  52. Jain S, Acharya SS. Management of rare coagulation disorders in 2018. Transfus Apher Sci 2018;57(6):705–712. DOI: 10.1016/j.transci. 2018.10.009.
  53. Go H, Ohto H, Nollet KE, et al. Risk factors and treatments for disseminated intravascular coagulation in neonates. Ital J Pediatr 2020;46(1):54. DOI: 10.1186/s13052-020-0815-7.
  54. Pichler E, Pichler L. The neonatal coagulation system and the vitamin K deficiency bleeding – a mini review. Wien Med Wochenschr 2008; 158(13–14):385–395. DOI: 10.1007/s10354-008-0538-7
  55. Rai RK, Luo J, Tulchinsky TH. Vitamin K supplementation to prevent hemorrhagic morbidity and mortality of newborns in India and China. World J Pediatr 2017;13(1):15–19. DOI: 10.1007/s12519-016-0062-6.
  56. Sankar MJ, Chandrasekaran A, Kumar P, et al. Vitamin K prophylaxis for prevention of vitamin K deficiency bleeding: a systematic review. J Perinatol 2016;36(1):S29–35. DOI: 10.1038/jp.2016.30.
  57. Bor O, Akgun N, Yakut A, et al. Late hemorrhagic disease of the newborn. Pediatr Int 2000;42(1):64–66. DOI: 10.1046/j.1442-200x. 2000.01173.x.
  58. Shearer MJ. Vitamin K deficiency bleeding (VKDB) in early infancy. Blood Rev 2009;23(2):49–59. DOI: 10.1016/j.blre.2008.06.001.
  59. Shanmugam NP, Bansal S, Greenough A, et al. Neonatal liver failure: aetiologies and management—state of the art. Eur J Pediatr. May 2011;170(5):573–581. DOI: 10.1007/s00431-010-1309-1.
  60. Cashen K, Meert K, Dalton H. Anticoagulation in neonatal ECMO: An enigma despite a lot of effort! Front Pediatr 2019;7:366. DOI: 10.3389/fped.2019.00366.
  61. Chlebowski MM, Baltagi S, Carlson M, et al. Clinical controversies in anticoagulation monitoring and antithrombin supplementation for ECMO. Crit Care 2020;24(1):19. DOI: 10.1186/s13054-020-2726-9.
  62. McMichael ABV, Zimmerman KO, Kumar KR, et al. Evaluation of effect of scheduled fresh frozen plasma on ECMO circuit life: A randomized pilot trial. Transfusion 2021;61(1):42–51. DOI: 10.1111/trf.16164.
  63. Yuan S, Tsukahara E, De La Cruz K, et al. How we provide transfusion support for neonatal and pediatric patients on extracorporeal membrane oxygenation. Transfusion 2013;53(6):1157–1665. DOI: 10.1111/j.1537-2995.2012.03688.x.
  64. Thayyil S, Milligan DW. Single versus double volume exchange transfusion in jaundiced newborn infants. Cochrane Database Syst Rev 2006;(4):CD004592. DOI: 10.1002/14651858.CD004592.pub2.
  65. Deorari AK, Paul VK, Shreshta L, et al. Symptomatic neonatal polycythemia: comparison of partial exchange transfusion with saline versus plasma. Indian Pediatr 1995;32(11):1167–1171.
  66. Roithmaier A, Arlettaz R, Bauer K, et al. Randomized controlled trial of Ringer solution versus serum for partial exchange transfusion in neonatal polycythaemia. Eur J Pediatr. Jan 1995;154(1):53–56. DOI: 10.1007/BF01972973.
  67. Krishnan L, Rahim A. Neonatal polycythemia. Indian J Pediatr 1997; 64(4):541–546. DOI: 10.1007/BF02737765.
  68. Dempsey EM, Barrington K. Short and long term outcomes following partial exchange transfusion in the polycythaemic newborn: a systematic review. Arch Dis Child Fetal Neonatal Ed 2006;91(1):F2–6. DOI: 10.1136/adc.2004.071431.
  69. de Waal KA, Baerts W, Offringa M. Systematic review of the optimal fluid for dilutional exchange transfusion in neonatal polycythaemia. Arch Dis Child Fetal Neonatal Ed 2006;91(1):F7–F10. DOI: 10.1136/adc.2004.063925.
  70. Dempsey EM, Barrington K. Crystalloid or colloid for partial exchange transfusion in neonatal polycythemia: a systematic review and meta-analysis. Acta Paediatr 2005;94(11):1650–1655. DOI: 10.1080/08035250500192748.
  71. Pandey S, Vyas GN. Adverse effects of plasma transfusion. Transfusion 2012;52 Suppl 1:65S–79S. DOI: 10.1111/j.1537-2995.2012.03663.x.
  72. Busch MP, Bloch EM, Kleinman S. Prevention of transfusion-transmitted infections. Blood 2019;133(17):1854–1864. DOI: 10.1182/blood-2018-11-833996.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.